Thomsen RW, Mailhac A, Lhde JB, Pottegrd A (2025) Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies
Animal studies show potential fetal risks, though human pregnancy data remain limited
This fat-burning peptide works through different mechanisms than GLP-1 agonists and remains more widely available
This is an area of growth because, increasingly, prescribers in the health industry are using these agents and stimulant medications for treating health concerns
Severe gastrointestinal disorders Individuals with conditions like gastroparesis (delayed stomach emptying) may experience worsening symptoms
2 However, this trial used the higher 2.4 mg dose (Wegovy), not the Ozempic doses